指南与共识痛风与晶体性关节病

痛风与晶体关节炎网络痛风命名共识声明的采纳情况

Uptake of the Gout and Crystal Arthritis Network Consensus Statements for Gout Nomenclature.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2023-12-06

本研究检索了美国风湿病学会和EULAR会议摘要,比较G-CAN共识声明发布前后两个时间段(2016-2017年与2020-2021年)痛风命名标签的使用情况。共纳入988篇摘要,结果显示「尿酸盐」和「痛风发作」等共识标签的使用率显著上升,而「慢性痛风」标签的使用率显著下降。

要点

  • G-CAN共识发布后,使用「尿酸盐」标签的摘要比例从57.2%(219/383)升至70.7%(164/232),P=0.001。
  • 使用「痛风发作」标签的摘要比例从34.3%(60/175)升至52.3%(57/109),P=0.003。
  • 使用「慢性痛风」标签的摘要比例从4.9%(29/596)降至2.0%(8/392),P=0.02。

核心结论

  • G-CAN共识标签的使用有所增加,但痛风命名仍不精确,需要进一步努力确保科学文献中痛风命名的一致性。

研究设计与样本

  • 本研究为对会议摘要的检索分析,检索了美国风湿病学会和EULAR会议摘要,比较G-CAN共识声明发布前后两个时间段(2016年1月1日至2017年12月31日与2020年1月1日至2021年12月31日)的命名使用情况。

主要发现

  • 共纳入988篇摘要,其中2016至2017年596篇,2020至2021年392篇。
  • 使用「尿酸盐」标签的摘要比例从2016至2017年的57.2%(219/383)升至2020至2021年的70.7%(164/232),P=0.001。
  • 使用「痛风发作」标签的摘要比例从2016至2017年的34.3%(60/175)升至2020至2021年的52.3%(57/109),P=0.003。
  • 使用「慢性痛风」标签的摘要比例从2016至2017年的4.9%(29/596)降至2020至2021年的2.0%(8/392),P=0.02。

关键数值与推荐

  • G-CAN共识声明推荐使用「尿酸盐」替代其他标签,推荐使用「痛风发作」描述发作状态,不推荐使用「慢性痛风」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2019, the Gout and Crystal Arthritis Network (G-CAN) published consensus statements for the nomenclature of disease elements and states in gout. The aim of this study was to determine adherence to the G-CAN consensus nomenclature statements since publication. METHODS: American College of Rheumatology and EULAR conference abstracts were searched using online databases for the keywords 'gout,' 'urate,' 'uric acid,' 'hyperuricaemia,' 'tophus,' and/or 'tophi' before and after publication of the consensus statements (January 1, 2016 to December 31, 2017 and January 1, 2020 to December 31, 2021, respectively). Abstracts were manually searched for labels used to reference gout disease elements and states. Use of the G-CAN-agreed labels, as well as alternatives, were compared between the two time periods. RESULTS: There were 988 abstracts included in the analysis: 596 in 2016 to 2017 and 392 in 2020 to 2021. Use of the agreed labels 'urate' and 'gout flare' increased between the two periods. There were 219 of 383 abstracts (57.2%) with the agreed label 'urate' in 2016 to 2017 compared with 164 of 232 (70.7%) in 2020 to 2021 (P = 0.001). There were 60 of 175 abstracts (34.3%) with the agreed label 'gout flare' in 2016 to 2017 compared with 57 of 109 (52.3%) in 2020 to 2021 (P = 0.003). Consistent with the G-CAN statement, use of the label 'chronic gout' reduced between the two time periods. There were 29 of 596 abstracts (4.9%) in 2016 to 2017 that used the label 'chronic gout' compared with 8 of 392 abstracts (2.0%) in 2020 to 2021 (P = 0.02). CONCLUSION: Use of G-CAN-agreed gout labels has increased, but gout nomenclature remains imprecise. Additional efforts are needed to ensure consistent use of agreed nomenclature for gout in the scientific literature.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Prendergast E, Dalbeth N, Bursill D, et al. Uptake of the Gout and Crystal Arthritis Network Consensus Statements for Gout Nomenclature. Arthritis Care Res (Hoboken). 2023. PMID: 37779482. doi:10.1002/acr.25250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。